Skip to main content
NGeneBio Co., Ltd. logo

NGeneBio Co., Ltd. — Investor Relations & Filings

Listed
Ticker · 354200 ISIN · KR7354200008 KO Professional, scientific and technical activities
Open in API
Filings indexed 348 across all filing types
Latest filing 2026-02-03 Capital/Financing Update
Country KR South Korea
Listing KO 354200 · 1 venue

About NGeneBio Co., Ltd.

https://www.ngenebio.com/en/index.asp

NGeneBio Co., Ltd. is a precision diagnostics company specializing in Next-Generation Sequencing (NGS) technology. The company develops and commercializes molecular diagnostic products, including in-vitro diagnostic (IVD) and companion diagnostic (CDx) solutions. Its primary focus is on oncology, offering NGS panels for the analysis of solid tumors and hematologic malignancies. Complementing its diagnostic assays, NGeneBio provides integrated bioinformatics software for comprehensive data analysis and interpretation. The company's portfolio also includes liquid biopsy technologies and personal genetic testing services, all aimed at providing precise genomic information to guide clinical decision-making.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the 'Decision to Sell Own Convertible Bonds' (자기전환사채매도결정). This involves the company's capital structure and financing activities, specifically the resale of previously acquired convertible bonds. This falls under the 'Capital/Financing Update' category as it details a specific financial transaction involving the company's debt instruments.
2026-02-03 Korean
[기재정정]기타경영사항(자율공시) (소규모 합병 승인 이사회 결의(주주총회 갈음) 결과 보고)
M&A Activity Classification · 95% confidence The document is a regulatory filing from NGeneBio regarding a 'small-scale merger' (소규모합병) with NGenePharma. It details the board resolution, the merger date, and the results of the shareholder opposition period. Since the document specifically concerns a merger transaction and its procedural updates, it falls under the M&A Activity category.
2026-01-30 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 98% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a merger decision (회사합병 결정) filed by NGeneBio. It details a correction (정정신고) to the merger schedule, specifically changing the merger date and related procedural dates. This type of filing is a standard regulatory disclosure in the Korean market (DART system) concerning corporate restructuring and M&A activity. Since it is a formal regulatory filing regarding a merger, it falls under the M&A Activity category.
2026-01-30 Korean
[기재정정]회사합병결정(종속회사의주요경영사항)
M&A Activity Classification · 100% confidence The document is a regulatory filing from NGeneBio regarding a 'Decision on Company Merger' (specifically a subsidiary merger). It details the merger method, purpose, schedule, and legal basis under the Capital Markets Act. Since it involves a corporate merger/takeover activity, it falls under the M&A Activity category.
2026-01-30 Korean
기타경영사항(자율공시) (소규모 합병 승인 이사회 결의(주주총회 갈음) 결과 보고)
M&A Activity Classification · 95% confidence The document is a regulatory filing from NGeneBio regarding the results of a board resolution for a small-scale merger (absorption of NGenePharma). It details the merger process, the lack of shareholder dissent exceeding the legal threshold, and the final approval of the merger. This falls under M&A activity (merger announcement/result).
2025-12-29 Korean
[기재정정]주요사항보고서(전환사채매수선택권행사자지정)
Regulatory Filings Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission in South Korea. It specifically concerns the cancellation of a contract related to the designation of a call option holder for convertible bonds (전환사채매수선택권행사자지정). This type of regulatory filing regarding capital structure and financial instruments does not fit into specific categories like dividends or director dealings, and is best classified as a general regulatory filing.
2025-12-29 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.